NICE Recommends Against Celgene’s Cancer Drug Abraxane

Drug Industry Daily
A A
The UK’s cost-effectiveness watchdog is recommending against coverage of Celgene’s cancer drug Ambraxane with gemcitabine for patients with previously untreated metastatic pancreatic cancer, citing its expensive price and limited benefits compared with current treatments.

To View This Article:

Login

Subscribe To Drug Industry Daily